公开(公告)号：WO02065895A3

公开(公告)日：2002-10-31

申请号：PCT/US0204814

申请日：2002-02-19

Applicant: BIOPHAN TECHNOLOGIES INC ,  CONNELLY PATRICK R ,  WEINER MICHAEL L ,  MACDONALD STUART G ,  HELFER JEFFREY L ,  FOSTER THOMAS H ,  GREATBATCH W ,  MILLER VICTOR

Inventor： CONNELLY PATRICK R ,  WEINER MICHAEL L ,  MACDONALD STUART G ,  HELFER JEFFREY L ,  FOSTER THOMAS H ,  GREATBATCH WILSON ,  MILLER VICTOR

IPC: A61N1/05 ,  A61N1/08 ,  A61N1/16 ,  A61N1/375

CPC classification number: G01R33/285 ,  A61N1/056 ,  A61N1/086 ,  A61N1/3718 ,  A61N1/375 ,  G01R33/288

Abstract: An electromagnetic immune tissue invasive system includes a primary device housing (1100 of Figure 30). The primary device housing having a control circuit therein (1110 of Figure 30). A shielding (1160 of Figure 30) is formed around the primary device housing (1100 of Figure 30) to shield the primary device housing and any circuits therein from electromagnetic interference. A lead system (1150 of Figure 30) transmits and receives signals between the primary device housing (1100 of Figure 30). The lead system (1150 of Figure 30) is either a fiber optic system or an electrically shielded electrical lead system.

Abstract translation: 电磁免疫组织侵入系统包括主装置外壳（图30的1100）。 主要装置外壳中具有控制电路（图30的1110）。 围绕主要装置外壳（图30的1100）形成屏蔽（图30的1160）以屏蔽主要装置外壳及其中的任何电路免受电磁干扰。 引导系统（图30的1150）在主要装置外壳（图30的1100）之间传输和接收信号。 引线系统（图30的1150）是光纤系统或电屏蔽电引线系统。

公开(公告)号：WO02072004A2

公开(公告)日：2002-09-19

申请号：PCT/US0206794

申请日：2002-03-06

Applicant: BIOPHAN LLC ,  CONNELLY PATRICK R ,  WEINER MICHAEL L

Inventor： CONNELLY PATRICK R ,  WEINER MICHAEL L

IPC: A61B5/00 ,  A61P3/10 ,  A61K

CPC classification number: A61B5/14546 ,  A61B5/14532 ,  A61B5/14557 ,  A61B5/415 ,  A61B5/4839

Abstract: An apparatus for regulating the concentration of insulin within the blood of a living organism, wherein said apparatus is comprised of an in vitro cell culture for producing insulin, an in vitro cell culture for producing glucagon, an in vitro cell culture for producing somatostatin, means for measuring the concentration of glucose within the blood of such living organism, means for measuring the concentration of insulin within the blood of such living organism, means for delivering a specified amount of insulin to the blood of such living organism, means for delivering a specified amount of glucagon to the blood of such living organism, means for delivering a specified amount of somatostain to the blood of such living organism, and means for reducing the amount of insulin within such blood of such living organism.

Abstract translation: 一种用于调节活体血液中胰岛素浓度的装置，其中所述装置包括用于产生胰岛素的体外细胞培养物，用于产生胰高血糖素的体外细胞培养物，用于产生生长抑素的体外细胞培养物 用于测量该生物体血液中葡萄糖浓度的方法，用于测量该活体内血液​​中胰岛素浓度的方法，用于将特定量的胰岛素输送到该生物体的血液的装置，用于递送指定的 胰高血糖素对该生物体血液的量，用于将特定量的生长激素递送至该生物体的血液的手段，以及用于减少该活体内血液​​中胰岛素的量的方法。

公开(公告)号：WO2002020826A3

公开(公告)日：2002-03-14

申请号：PCT/US2001/027371

申请日：2001-09-04

Applicant: THE ALTHEXIS COMPANY, INC. ,  FAERMAN, Carlos, H. ,  CONNELLY, Patrick

Inventor： FAERMAN, Carlos, H. ,  CONNELLY, Patrick

IPC: G06F17/30

Abstract: An electronic database for identification of enzyme substrate and enzyme inhibitor structures that are structurally similar to a submitted chemical structure is provided. The enzyme substrate and enzyme inhibitor structures can be linked by numerous parameters, such as by Enzyme Classification Number. The database can be used to identify potential therapeutics for newly discovered enzymes or enzymes families.

公开(公告)号：WO2008106151A2

公开(公告)日：2008-09-04

申请号：PCT/US2008/002568

申请日：2008-02-27

Applicant: VERTEX PHARMACEUTICALS INCORPORATED ,  CONNELLY, Patrick, R. ,  KADIYALA, Irina ,  STAVROPOLUS, Kathy ,  ZHANG, Yuegang ,  JOHNSTON, Steve ,  BHISETTI, Govinda, Rao ,  JURKAUSKAS, Valdas ,  ROSE, Peter

Inventor： CONNELLY, Patrick, R. ,  KADIYALA, Irina ,  STAVROPOLUS, Kathy ,  ZHANG, Yuegang ,  JOHNSTON, Steve ,  BHISETTI, Govinda, Rao ,  JURKAUSKAS, Valdas ,  ROSE, Peter

CPC classification number: C07K5/0812 ,  C07D403/12

Abstract: The invention relates to compositions and co-crystals each comprising VX-950 and a co-crystal former selected from the group consisting of 4-hydroxybenzoic acid, 4-amino salicylic acid, phenylalanine, threonline, tartaric acid, adipic acid, succinic acetate, proline, methyl 4-hydroxybenzoate, anthranilic acid, and d-Biotin. Also within the scope of this invention are methods of making and using the same.

Abstract translation: 本发明涉及各自包含VX-950和选自4-羟基苯甲酸，4-氨基水杨酸，苯丙氨酸，苏氨酸，酒石酸的共晶体形成物的组合物和共晶体 酸，己二酸，琥珀酸乙酸酯，脯氨酸，4-羟基苯甲酸甲酯，邻氨基苯甲酸和d-生物素。 也在本发明的范围内的是制造和使用它们的方法。

公开(公告)号：WO2004075855A3

公开(公告)日：2004-09-10

申请号：PCT/US2004/005688

申请日：2004-02-26

Applicant: BIOMED SOLUTIONS, LLC ,  CONNELLY, Patrick, R. ,  HELFER, Jeffrey, L. ,  CUSTER, Andrew, W. ,  KIM, Michael, B.

Inventor： CONNELLY, Patrick, R. ,  HELFER, Jeffrey, L. ,  CUSTER, Andrew, W. ,  KIM, Michael, B.

IPC: C12M1/34 ,  C12M1/36 ,  C12M1/38 ,  C12M3/00 ,  C12Q1/68 ,  G01N3/00 ,  G01N21/00 ,  G01N31/22 ,  G01N33/53 ,  G01N33/543 ,  G01N33/551 ,  G01N33/544 ,  G01N33/567

Abstract: A process for the in vivo treatment of the bodily fluid of a biological organism is presented, wherein the organism is implanted with a capture device containing a target specific binding agent. The bodily fluid of the donor is brought into contact with the binding agent and the desired cellular components are allowed to bind with the binding agent.

公开(公告)号：WO2002065895A2

公开(公告)日：2002-08-29

申请号：PCT/US2002/004814

申请日：2002-02-19

Applicant: BIOPHAN TECHNOLOGIES, INC. ,  CONNELLY, Patrick, R. ,  WEINER, Michael, L. ,  MACDONALD, Stuart, G. ,  HELFER, Jeffrey, L. ,  FOSTER, Thomas, H. ,  GREATBATCH, Wilson ,  MILLER, Victor

Inventor： CONNELLY, Patrick, R. ,  WEINER, Michael, L. ,  MACDONALD, Stuart, G. ,  HELFER, Jeffrey, L. ,  FOSTER, Thomas, H. ,  GREATBATCH, Wilson ,  MILLER, Victor

IPC: A61B

CPC classification number: G01R33/285 ,  A61N1/056 ,  A61N1/086 ,  A61N1/3718 ,  A61N1/375 ,  G01R33/288

Abstract: An electromagnetic immune tissue invasive system includes a primary device housing (1100 of Figure 30). The primary device housing having a control circuit therein (1110 of Figure 30). A shielding (1160 of Figure 30) is formed around the primary device housing (1100 of Figure 30) to shield the primary device housing and any circuits therein from electromagnetic interference. A lead system (1150 of Figure 30) transmits and receives signals between the primary device housing (1100 of Figure 30). The lead system (1150 of Figure 30) is either a fiber optic system or an electrically shielded electrical lead system.

Abstract translation: 电磁免疫组织侵入系统包括主要装置壳体（图30的1100）。 主装置壳体中具有控制电路（图30的1110）。 围绕主设备外壳（图30的1100）形成屏蔽层（图30的1160），以屏蔽主设备外壳及其中的任何电路免受电磁干扰。 引导系统（图30的1150）在主设备外壳（图30的1100）之间传送和接收信号。 引导系统（图30的1150）是光纤系统或电屏蔽电引线系统。

公开(公告)号：WO1994001217A1

公开(公告)日：1994-01-20

申请号：PCT/US1993006507

申请日：1993-07-09

Applicant: VERTEX PHARMACEUTICALS INCORPORATED ,  CONNELLY, Patrick, R.

Inventor： VERTEX PHARMACEUTICALS INCORPORATED

IPC: B01L07/00

CPC classification number: B01L7/54 ,  B01L7/00 ,  G01N25/4846

Abstract: A temperature gradient calorimeter and method of calculating heats of reactions is disclosed. The calorimeter has a two dimensional array of reaction chambers located in a thermally conductive substrate. A first heat transfer medium is in thermal contact with the thermal conductive substrate and is located at one region of the array of reaction chambers. A second heat transfer medium is in thermal contact with the thermal conductive substrate and is located on the opposite side of the array from the first heat transfer medium. The first and second heat transfer mediums are at two different temperatures. That temperature difference produces a temperature gradient across the array of reaction chambers. The fluorescence intensities are measured for reactant samples located in the array of reaction chambers. By inserting the fluorescence intensity data into thermodynamic equations expressing the degree of advancement and the heat of reaction, the heat of reaction for the reaction process of the sample can be determined.

Abstract translation: 公开了一种温度梯度量热计和计算反应热的方法。 量热计具有位于导热基板中的反应室的二维阵列。 第一传热介质与导热基板热接触并且位于反应室阵列的一个区域。 第二传热介质与导热基板热接触并且位于阵列的与第一传热介质相反的一侧。 第一和第二传热介质处于两个不同的温度。 该温度差在反应室阵列上产生温度梯度。 测量位于反应室阵列中的反应物样品的荧光强度。 通过将荧光强度数据插入到表达进化度和反应热的热力学方程中，可以确定样品的反应过程的反应热。

公开(公告)号：WO2016057730A1

公开(公告)日：2016-04-14

申请号：PCT/US2015/054577

申请日：2015-10-07

Applicant: STROHMEIER, Mark ,  CAESAR, JR., John P. ,  CONNELLY, Patrick Raymond ,  FAWAZ, Majed ,  LUSS-LUSIS, Eduard ,  MCCLAIN, Brian R. ,  MEDEK, Ales ,  MIAO, Hai ,  NTI-ADDAE, Kwame Wiredu ,  YIN, Ping ,  ZHANG, Yuegang

Inventor： STROHMEIER, Mark ,  CAESAR, JR., John P. ,  CONNELLY, Patrick Raymond ,  FAWAZ, Majed ,  LUSS-LUSIS, Eduard ,  MCCLAIN, Brian R. ,  MEDEK, Ales ,  MIAO, Hai ,  NTI-ADDAE, Kwame Wiredu ,  YIN, Ping ,  ZHANG, Yuegang

IPC: C07D215/56

CPC classification number: C07D215/56 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  C07B2200/13 ,  C07C69/18 ,  C07C69/30 ,  C07C69/34 ,  C07C69/58 ,  C07C69/587

Abstract: The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.

Abstract translation: 本公开内容涉及包含N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1）和共 - 成型机及其制备方法。 本公开还涉及包含共晶形式的药物组合物，以及其治疗方法和试剂盒。

公开(公告)号：WO2008106151A3

公开(公告)日：2008-11-06

申请号：PCT/US2008002568

申请日：2008-02-27

Applicant: VERTEX PHARMA ,  CONNELLY PATRICK R ,  KADIYALA IRINA ,  STAVROPOLUS KATHY ,  ZHANG YUEGANG ,  JOHNSTON STEVE ,  BHISETTI GOVINDA RAO ,  JURKAUSKAS VALDAS ,  ROSE PETER

Inventor： CONNELLY PATRICK R ,  KADIYALA IRINA ,  STAVROPOLUS KATHY ,  ZHANG YUEGANG ,  JOHNSTON STEVE ,  BHISETTI GOVINDA RAO ,  JURKAUSKAS VALDAS ,  ROSE PETER

IPC: C07D403/12 ,  A61K31/497 ,  A61K38/07 ,  C07K5/10

CPC classification number: C07K5/0812 ,  C07D403/12

Abstract: The invention relates to compositions and co-crystals each comprising VX-950 and a co-crystal former selected from the group consisting of 4-hydroxybenzoic acid, 4-amino salicylic acid, phenylalanine, threonline, tartaric acid, adipic acid, succinic acetate, proline, methyl 4-hydroxybenzoate, anthranilic acid, and d-Biotin. Also within the scope of this invention are methods of making and using the same.

Abstract translation: 本发明涉及各自包含VX-950和选自4-羟基苯甲酸，4-氨基水杨酸，苯丙氨酸，苏氨酸，酒石酸，己二酸，琥珀酸乙酯， 脯氨酸，4-羟基苯甲酸甲酯，邻氨基苯甲酸和d-生物素。 在本发明的范围内也是制造和使用本发明的方法。

公开(公告)号：WO2007079139A9

公开(公告)日：2007-11-29

申请号：PCT/US2006049421

申请日：2006-12-28

Applicant: VERTEX PHARMA ,  HURTER PATRICIA ,  ROWE WILLIAM ,  YOUNG CHRISTOPHER R ,  COSTACHE ADRIANA ,  CONNELLY PATRICK ,  KRAWIEC MARIUSZ ,  GONG YUCHUAN ,  FENG YUSHI ,  TRUDEAU MARTIN

Inventor： HURTER PATRICIA ,  ROWE WILLIAM ,  YOUNG CHRISTOPHER R ,  COSTACHE ADRIANA ,  CONNELLY PATRICK ,  KRAWIEC MARIUSZ ,  GONG YUCHUAN ,  FENG YUSHI ,  TRUDEAU MARTIN

IPC: A01N43/40 ,  A61K31/445

CPC classification number: A61K31/47 ,  A61K2300/00 ,  C07B2200/13 ,  C07D215/56 ,  Y10T428/2982

Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

Abstract translation: 本发明涉及N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1）的固体形式，药物组合物 及其方法。